<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736706</url>
  </required_header>
  <id_info>
    <org_study_id>6482-012</org_study_id>
    <secondary_id>2020-002216-52</secondary_id>
    <secondary_id>MK-6482-012</secondary_id>
    <nct_id>NCT04736706</nct_id>
  </id_info>
  <brief_title>A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)</brief_title>
  <official_title>An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus&#xD;
      belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab&#xD;
      plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell&#xD;
      carcinoma (ccRCC).&#xD;
&#xD;
      The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to&#xD;
      pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall&#xD;
      survival (OS), in advanced ccRCC participants and (2) pembrolizumab/quavonlimab plus&#xD;
      lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in&#xD;
      advanced ccRCC participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">October 29, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 29, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR based on RECIST 1.1 will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 66 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR</measure>
    <time_frame>Up to approximately 66 months</time_frame>
    <description>For participants who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR based on RECIST 1.1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced At least One Adverse Event (AE)</measure>
    <time_frame>Up to approximately 66 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience at least one AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinue Study Treatment Due to an AE</measure>
    <time_frame>Up to approximately 66 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1431</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + Belzutifan + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 18 administrations (up to ~2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab/Quavonlimab + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pembrolizumab/quavonlimab (co-formulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered IV Q6W for up to 18 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 18 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 400 mg administered Q6W via IV infusion</description>
    <arm_group_label>Pembrolizumab + Belzutifan + Lenvatinib</arm_group_label>
    <arm_group_label>Pembrolizumab + Lenvatinib</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belzutifan</intervention_name>
    <description>Belzutifan 120 mg administered QD via oral tablet</description>
    <arm_group_label>Pembrolizumab + Belzutifan + Lenvatinib</arm_group_label>
    <other_name>MK-6482</other_name>
    <other_name>PT2977</other_name>
    <other_name>WELIREG™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab/Quavonlimab</intervention_name>
    <description>Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion</description>
    <arm_group_label>Pembrolizumab/Quavonlimab + Lenvatinib</arm_group_label>
    <other_name>MK-1308A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib 20 mg administered QD via oral capsule</description>
    <arm_group_label>Pembrolizumab + Belzutifan + Lenvatinib</arm_group_label>
    <arm_group_label>Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_label>Pembrolizumab/Quavonlimab + Lenvatinib</arm_group_label>
    <other_name>MK-7902</other_name>
    <other_name>E7080</other_name>
    <other_name>LENVIMA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has histologically confirmed diagnosis of RCC with clear cell component&#xD;
&#xD;
          -  Has received no prior systemic therapy for advanced ccRCC&#xD;
&#xD;
          -  Male participants are abstinent from heterosexual intercourse or agree to use&#xD;
             contraception during and for at least 7 days after last dose of study intervention&#xD;
             with belzutifan and lenvatinib&#xD;
&#xD;
          -  Female participants are not pregnant or breastfeeding and are either not a woman of&#xD;
             child-bearing potential (WOCBP) or use a contraceptive method that is highly effective&#xD;
             or are abstinent from heterosexual intercourse during the intervention period and for&#xD;
             at least 120 days after pembrolizumab or pembrolizumab/quavonlimab or for at least 30&#xD;
             days after last dose of lenvatinib or belzutifan, whichever occurs last&#xD;
&#xD;
          -  Has adequately controlled blood pressure with or without antihypertensive medications&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
          -  Participants receiving bone resorptive therapy must have therapy initiated at least 2&#xD;
             weeks prior to randomization/allocation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 3 years&#xD;
&#xD;
          -  Has had major surgery, other than nephrectomy within 4 weeks prior to randomization&#xD;
&#xD;
          -  Has known central nervous system (CNS) metastases and/or carcinomatous meningitis&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks prior to first dose of study&#xD;
             intervention&#xD;
&#xD;
          -  Has hypoxia or requires intermittent supplemental oxygen or requires chronic&#xD;
             supplemental oxygen&#xD;
&#xD;
          -  Has clinically significant cardiac disease within 12 months from first dose of study&#xD;
             intervention&#xD;
&#xD;
          -  Has a history of interstitial lung disease&#xD;
&#xD;
          -  Has symptomatic pleural effusion; a participant who is clinically stable following&#xD;
             treatment of this condition is eligible&#xD;
&#xD;
          -  Has preexisting gastrointestinal or non-gastrointestinal fistula&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             or any other form of immunosuppressive therapy within 7 days prior to the first dose&#xD;
             of study treatment&#xD;
&#xD;
          -  Has a known psychiatric or substance abuse disorder that would interfere with&#xD;
             requirements of the study&#xD;
&#xD;
          -  Has received a live or live-attenuated vaccine within 30 days before the first dose of&#xD;
             study drug; killed vaccines are allowed&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in the past 2&#xD;
             years&#xD;
&#xD;
          -  Has a history of noninfectious pneumonitis that required steroids or has current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Has a known history of Hepatitis B&#xD;
&#xD;
          -  Has radiographic evidence of intratumoral cavitation, encasement or invasion of a&#xD;
             major blood vessel&#xD;
&#xD;
          -  Has clinically significant history of bleeding within 3 months prior to randomization&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham ( Site 0010)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-934-3411</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology Oncology Santa Monica ( Site 0048)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-633-8400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital ( Site 0024)</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>860-972-4700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advent Health Hematology &amp; Oncology ( Site 0003)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-303-2024</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC ( Site 0057)</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>706-353-2990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute ( Site 0012)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-778-1900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center ( Site 0040)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-942-3732</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkview Cancer Institute ( Site 0088)</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>833-724-8326</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - St. Matthews ( Site 0065)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>502-899-3366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center ( Site 0049)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>504-842-3910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialists ( Site 0082)</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>207-303-3300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ( Site 0094)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-724-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center ( Site 0089)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-667-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute ( Site 0093)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-632-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital &amp; Medical Center ( Site 0090)</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>781-744-8400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital ( Site 0038)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-2600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer &amp; Hematology Centers of Western Michigan ( Site 0018)</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>616-885-1462</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center - HealthPartners/Park Nicollet ( Site 0005)</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>952-993-6705</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regions Hospital ( Site 0095)</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>651-254-1517</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute ( Site 0032)</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>716-845-3159</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University ( Site 0071)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503-494-1080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Center ( Site 0073)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-789-7816</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center Knoxville ( Site 0019)</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>865-305-8780</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center ( Site 0069)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>615-936-8422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UTSW Medical Center ( Site 0015)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-648-7097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Confluence Health | Wenatchee Valley Hospital &amp; Clinics ( Site 0061)</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-436-6245</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital ( Site 4006)</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61287389744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Macquarie University ( Site 4007)</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6129812 3526</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital ( Site 4004)</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61403657869</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health ( Site 4008)</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61412191080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital ( Site 4009)</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61298123526</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Investigacion Cancer James Lind ( Site 0402)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4780000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56452982404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IC La Serena Research ( Site 0403)</name>
      <address>
        <city>La Serena</city>
        <state>Coquimbo</state>
        <zip>1720430</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56512386127</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Servicios Medicos Urumed ( Site 0405)</name>
      <address>
        <city>Rancagua</city>
        <state>Region M. De Santiago</state>
        <zip>2852424</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56989022206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez ( Site 0400)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7500921</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+569228205700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradfordhill-Clinical Area ( Site 0401)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56229490970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda. ( Site 0502)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>573008457996</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0505)</name>
      <address>
        <city>Valledupar</city>
        <state>Cesar</state>
        <zip>200001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573128385292</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Administradora Country SA - Clinica del Country ( Site 0504)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>3108627483</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología E.S.E. ( Site 0503)</name>
      <address>
        <city>Bogotá</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111511</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5714320160</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncólogos del Occidente S.A ( Site 0501)</name>
      <address>
        <city>Pereira</city>
        <state>Risaralda</state>
        <zip>660001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573155313926</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardiovascular de Colombia ( Site 0506)</name>
      <address>
        <city>Floridablanca</city>
        <state>Santander</state>
        <zip>681004</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573215433439</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masarykuv onkologicky ustav ( Site 2203)</name>
      <address>
        <city>Brno</city>
        <state>Brno-mesto</state>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420543132216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne ( Site 2205)</name>
      <address>
        <city>Brno</city>
        <state>Brno-mesto</state>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420543183073</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice AGEL Novy Jicin a.s. ( Site 2202)</name>
      <address>
        <city>Novy Jicin</city>
        <state>Moravskoslezsky Kraj</state>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420556416180</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava ( Site 2208)</name>
      <address>
        <city>Ostrava</city>
        <state>Moravskoslezsky Kraj</state>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420597372123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc ( Site 2200)</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420588444295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni Thomayerova nemocnice ( Site 2201)</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420261082531</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>2 LF UK a FN Motol ( Site 2207)</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420224434700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital ( Site 1700)</name>
      <address>
        <city>Herlev</city>
        <state>Hovedstaden</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>38683868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital ( Site 1701)</name>
      <address>
        <city>Odense</city>
        <state>Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4566113333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TAYS ( Site 1801)</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358 3 31163082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopion Yliopistollinen Sairaala ( Site 1803)</name>
      <address>
        <city>Kuopio</city>
        <state>Pohjois-Savo</state>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358 44 717 2943</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HYKS ( Site 1800)</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358401440338</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TYKS ( Site 1802)</name>
      <address>
        <city>Turku</city>
        <state>Varsinais-Suomi</state>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35823130729</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz ( Site 1205)</name>
      <address>
        <city>Besancon</city>
        <state>Doubs</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33370632403</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud ( Site 1214)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33531155829</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Francois Chenieux ( Site 1209)</name>
      <address>
        <city>Limoges</city>
        <state>Haute-Vienne</state>
        <zip>87039</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33555454800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud Hospices Civils de Lyon ( Site 1203)</name>
      <address>
        <city>Pierre Benite</city>
        <state>Rhone</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33478864324</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy ( Site 1207)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142115252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico Integral de Cancerologia CEMIC ( Site 0701)</name>
      <address>
        <city>Salcaja</city>
        <state>Quetzaltenango</state>
        <zip>09002</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50259458053</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica ( Site 0700)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50222781269</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grupo Angeles SA ( Site 0705)</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50223857572</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio Nuestra Senora del Pilar ( Site 0702)</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50258190718</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medi-K Cayala ( Site 0703)</name>
      <address>
        <city>Guatemala</city>
        <zip>01016</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50222912323</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Regional de Sub Especialidades Medicas SA ( Site 0704)</name>
      <address>
        <city>Quetzaltenango</city>
        <zip>09001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50277674235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 2308)</name>
      <address>
        <city>Kecskemét</city>
        <state>Bacs-Kiskun</state>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3676519853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 2309)</name>
      <address>
        <city>Gyula</city>
        <state>Bekes</state>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36704397973</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jasz - Nagykun Szolnok megyei Hetenyi Geza Korhaz - Rendelointezet ( Site 2300)</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209323256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Markusovszky Egyetemi Oktatokorhaz ( Site 2303)</name>
      <address>
        <city>Szombathely</city>
        <state>Vas</state>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3694515665</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet ( Site 2304)</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3612248600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 2301)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3652255840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center ( Site 4202)</name>
      <address>
        <city>Goyang-si</city>
        <state>Kyonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82319201505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital ( Site 4205)</name>
      <address>
        <city>Daejeon</city>
        <state>Taejon-Kwangyokshi</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82422808369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital ( Site 4206)</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8229206267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 4201)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220721672</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 4204)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222288054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 4203)</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230106095</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 4200)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234101767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sultan Ismail ( Site 4303)</name>
      <address>
        <city>Johor Bahru</city>
        <state>Johor</state>
        <zip>81100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6073565000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universiti Malaya Medical Centre ( Site 4300)</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60379492120</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0610)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523315145351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>I CAN Oncology SA de SV ( Site 0601)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+528125558165</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica de Oaxaca ( Site 0605)</name>
      <address>
        <city>Oaxaca</city>
        <zip>68020</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+52 951 547 3137</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus universitetssykehus ( Site 2000)</name>
      <address>
        <city>Lorenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>47 67 96 00 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soerlandet sykehus HF Kristiansand ( Site 2007)</name>
      <address>
        <city>Kristiansand</city>
        <state>Aust-Agder</state>
        <zip>4615</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4738146658</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helse Bergen HF - Haukeland Universitetssykehus ( Site 2002)</name>
      <address>
        <city>Bergen</city>
        <state>Hordaland</state>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>47 55 97 50 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sykehuset Østfold HF Kalnes ( Site 2003)</name>
      <address>
        <city>Gralum</city>
        <state>Ostfold</state>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4791508600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital HF ( Site 2005)</name>
      <address>
        <city>Trondheim</city>
        <state>Sor-Trondelag</state>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>47 72 57 30 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus Radiumhospitalet ( Site 2001)</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4797666192</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radomskie Centrum Onkologii ( Site 2418)</name>
      <address>
        <city>Radom</city>
        <state>Mazowieckie</state>
        <zip>26-600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>504057071</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luxmed Onkologia sp. z o. o. ( Site 2412)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48691666578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2405)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4848225462331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Przychodnia Lekarska KOMED ( Site 2419)</name>
      <address>
        <city>Konin</city>
        <state>Wielkopolskie</state>
        <zip>62-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48632428009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Panskiego UM im. K. Marcinkowskiego ( Site 2406)</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48618549038</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki im. Mikolaja Kopernika ( Site 2407)</name>
      <address>
        <city>Koszalin</city>
        <state>Zachodniopomorskie</state>
        <zip>75-581</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48943488930</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivanovo Regional Oncology Dispensary ( Site 2615)</name>
      <address>
        <city>Ivanovo</city>
        <state>Ivanovskaya Oblast</state>
        <zip>153040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74932569489</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 2609)</name>
      <address>
        <city>Krasnoyarsk</city>
        <state>Krasnoyarskiy Kray</state>
        <zip>660133</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73912224030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Loginov Moscow Clinical Scientific Center ( Site 2604)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+784953043039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow Oncological Clinical Dispensary #1 ( Site 2619)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74955369406</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nizhniy Novgorod Region Oncology Dispensary ( Site 2621)</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <state>Nizhegorodskaya Oblast</state>
        <zip>603081</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78314643777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FBHI Privolzhsky District Medical Center of the FMBA ( Site 2611)</name>
      <address>
        <city>Nizhny Novgorod</city>
        <state>Nizhegorodskaya Oblast</state>
        <zip>603074</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>79200225137</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 2617)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78125968538</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City clinical oncological dispensary ( Site 2605)</name>
      <address>
        <city>Sankt-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78129315267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Care Langenhoven Drive Oncology Centre ( Site 3009)</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>27413630581</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ. Pretoria and Steve Biko Academic Hospitals ( Site 3002)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>012 354 2022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancercare Rondebosch Oncology ( Site 3005)</name>
      <address>
        <city>Rondebosch</city>
        <state>Western Cape</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27861999914</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia - ICO ( Site 1502)</name>
      <address>
        <city>L Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932607744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla ( Site 1501)</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34942202525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Girona Doctor Josep Trueta ( Site 1500)</name>
      <address>
        <city>Girona</city>
        <state>Gerona</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34972225828</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos ( Site 1503)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913303000 x3133</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre ( Site 1505)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913908339</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria ( Site 1504)</name>
      <address>
        <city>Malaga</city>
        <zip>29016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34951032508</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lanssjukhuset Ryhov ( Site 2103)</name>
      <address>
        <city>Jonkoping</city>
        <state>Jonkopings Lan</state>
        <zip>551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46102425942</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna ( Site 2100)</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholms Lan</state>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46851770000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset ( Site 2105)</name>
      <address>
        <city>Uppsala</city>
        <state>Uppsala Lan</state>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46186110000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus ( Site 2106)</name>
      <address>
        <city>Umea</city>
        <state>Vasterbottens Lan</state>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46907850000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation. Kaohsiung Branch ( Site 4405)</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886773171233267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital ( Site 4403)</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886 4 23592525 ext.5121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 4404)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 4401)</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88623123456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital ( Site 4402)</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886228757519 ext. 306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara Universitesi Tip Fakultesi ( Site 2902)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0903125957112</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tıp Fakultesi ( Site 2903)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903123055000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trakya University Medical Faculty Balkan Oncology Hospital ( Site 2906)</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322480988</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 2900)</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324167355</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2901)</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905063509061</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Hastanesi ( Site 2904)</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323904387</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Universitesi Tip Fakultesi Hastanesi ( Site 2905)</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902324122222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cherkasy Regional Oncology Dispensary ( Site 2704)</name>
      <address>
        <city>Cherkasy</city>
        <state>Cherkaska Oblast</state>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380 63 7374213</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chernihiv Medical Center of Modern Oncology ( Site 2709)</name>
      <address>
        <city>Chernihiv</city>
        <state>Chernihivska Oblast</state>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380631587640</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 2710)</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+80504545480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical oncology dispensary of Dnipro ( Site 2700)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49055</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+38050 481 35 46</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Hospital-Urology department ( Site 2707)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380 95 5171872</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Oncology Clinical Dispensary ( Site 2711)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380 34 2507355</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Oncology Center of Kharkiv ( Site 2708)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380 63 2775872</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reg. Clinical Center of Urology and Nephrology n.a. V. I. Shapoval ( Site 2715)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380 99 6528666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncology Center ( Site 2706)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380938582050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lviv State Regional Oncological Center ( Site 2712)</name>
      <address>
        <city>Lviv</city>
        <state>Lvivska Oblast</state>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380 97 3317578</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <keyword>Hypoxia inducible factor (HIF)</keyword>
  <keyword>Hypoxia inducible factor 1B (HIF-1B)</keyword>
  <keyword>Hypoxia inducible factor 2 alpha (HIF-2 alpha)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

